For personal use only. on October 23, 2017. by guest www.bloodjournal.org From CORRESPONDENCE B cells, T cells, and natural killer (NK) cells. CD39 represents a novel lymphocyte activation antigen on both T and NK cells, with potential relevance for the monitoring of in vivo immune activation. Delayed induction and prolonged expression of CD39 presents a unique feature when compared with established leukocyte activation antigens such as CD25 and CD7 1 .? However. the in vivo relevance of CD39 on spontaneously and therapeutically activated T and NK cells has not been studied in detail.
We analyzed CD39 expression in 103 patients with advanced malignancies (77 renal cell carcinomas, 13 melanomas, 8 colorectal carcinomas, 2 mesotheliomas, 1 B-cell lymphoma, 1 malignant fibrous histiocytoma, and 1 malignant schwannoma) receiving an immunomodulatory therapy consisting of low-dose recombinant IL-2 (rIL-2) at doses between 4.8 and 18.0 Mio lU/m*/day administered subcutane~usly.'~~ Because CD39 is constitutively expressed on B lymphocytes, only the number of CD39' peripheral blood lymphocytes exceeding CD20' B cells was evaluated. Absolute cell counts were enumerated before, during (week 3), and after one treatment course (week 7) using flow cytometry.' Effective therapeutic immune activation was monitored by measuring the clinical response of the tumor lesions of treated patients according to World Health Organization criteria."
We observed a generalized expansion of circulating CD39+ lymphocytes with maximum levels in patients who achieved complete or partial tumor remission on therapy. This increase relates to de novo expression on both T and NK cells. However, in this study, no further subdivision was made between those two cc11 typcs. . Figure I gives the mean values of circulating T or NK cells (+ standard errors) on day 0 and after 3 and 6 weeks of immunotherapy for all patients (n = 103). for patients who achieved a complete or partial remission (CRPR, n = 26). for patients with stable disease (SD, n = 51). and for patients with progressive disease (PD, n = 26).
In all patients (n = 103). a 4.4-fold (P < .oooOI) increase from a mean of 52/pL (range, 0 to 288/pL) on day 0 to a mean of 227/ pL (range, 0 to 734/pL) on week 3 was observed, followed by a (week 3, D) , and after (week 7, ) rll-2-based immunomodulating therapy in a total of 103 advanced tumor patients were analyzed. Mean values (+ standard errors) are given for all patients (CR/PR, n = 26; SD, n = 51; PD, n = 261. The treatment-related increase of circulating CD39' cells was found to be significant in all response groups. Patient subgroups exhibited no statistically significant differences as to sex and age. 3827 significant decrease (P < .005) from week 3 levels to a mean of 147/pL (range, 0 to 1,44O/pL) on week 7.
Patients achieving a CRPR (n = 26) showed a significant (P < .OOOI) 7.6-fold increase from a mean of 39/pL on day 0 (range, 0 to 2 18/pL) to a mean of 298/pL (range, 0 to 656/pL) after 3 weeks of therapy. After completion of the treatment course, a significant ( P < .002) decrease to a mean of 179/pL (range, 0 to 871/pL) on week 7 was observed.
A significant (P < .oooO1) 3.3-fold increase of circulating CD39' T or NK cells was found in patients with stable disease (n = 51) from a mean of 67/pL (range, 0 to 288/pL) before therapy up to a mean of 222/pL (range, 0 to 734/pL) after 3 weeks of therapy, followed by a significant decrease (P < .01) to a mean of 162/pL (range, 0 to 1,44O/pL) after 6 weeks of therapy.
Patients with tumor progression (n = 26) showed a significant ( P < .OOOI) 4.6-fold increase from a mean of 36/pL (range, 0 to 152/ pL) on day 0 to a mean of 167/pL (range, 0 to 473/pL) on week 3. This increase was followed by a significant ( P < 032) decrease to a mean of 84/pL (range, 0 to 504/pL) after completion of the treatment course (week 7).
Comparison of response groups yielded significant differences between patients who had a complete or partial remission and those who showed further progression of disease on week 3 (P < .W) and after therapy (week 7, P < .M). Although patients who presented with stable disease exhibited significantly lower mean CD39' lymphocyte levels at week 3 when compared with patients achieving a complete or partial tumor rcmission ( P i .04), they still showed significantly higher posttherapy levels ( P < .03) when compared with patients with progressive disease. Comparable results were obtained when evaluating renal cell carcinoma patients only.
Our observations suggest that CD39 is a valuable new marker for the study of long-term immune activation in tumor patients. Further studies will help to establish the clinical relevance of CD39 for the immunomonitoring of other diseases, including chronic immune disorders and infections.
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